Allergies to lipid transfer proteins involve severe adverse reactions; thus， effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed to maintain immunogenicity; thus， the aim is to design novel hypoallergenic Pru p 3 variants and evaluate the applicability for treatment of peach allergy.
Allergies to lipid transfer proteins involve severe adverse reactions; thus， effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed to maintain immunogenicity; thus， the aim is to design novel hypoallergenic Pru p 3 variants and evaluate the applicability for treatment of peach allergy.
